Preprint / Version 1

Vaccine Approaches for Pandemic COVID-19

An Overview


  • Arpit Saxena Hester Biosciences Limited, Ahmadabad (382721), India
  • Lalit Mohan Jeena Department of Gynaecology and obstructive, Maulana Azad Medical College, Delhi
  • Joy K Pal Research and Development, Hester Biosciences Ltd, Ahmedabad, India



The coronavirus strain, SARS-CoV-2 causative agent of the pandemic viral pneumonia disease COVID-19, identified in the late 2019. Unfortunately, there is no vaccine or therapeutics available to control the disease. Although, earlier research efforts of SARS pandemic (2003) provides the precious information to the researchers for fast track vaccine development. Research efforts for vaccine development of COVID-19 pandemic are unprecedented in terms of promising time period. The inactivated whole virus-based SARS-CoV-2 vaccine is first one developed and entered into clinical trial. However, later on after announce of complete genome sequence of SARS-CoV-2, vaccine based on recombinant viral vector, nucleic acid and immunogenic fragment also introduced. Previous experience of undesired immunopotentiation in SARS-CoV studies represents, vaccine safety should be the main concern.  Researchers believe that next generation vaccine approaches using recombinant technology such as viral vector or subunit protein-based vaccine will be more effective and safer. This review describes brief information of the major vaccine candidates and the current scenario of vaccine approaches against COVID-19 pandemic.


COVID-19, Vaccine, SARS-CoV-2


Download data is not yet available.


Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International journal of antimicrobial agents. 2020 Feb 17:105924.

Yadav PD, Potdar VA, Choudhary ML, Nyayanit DA, Agrawal M, Jadhav SM, Majumdar TD, Shete-Aich A, Basu A, Abraham P, Cherian SS. Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian Journal of Medical Research. 2020 Feb 1;151(2):200.

Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell host & microbe. 2020 Feb 7.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020 Jan 24.

Tomasi D. Coronavirus disease (COVID-19). A socio epidemiological analysis. Bennington, VT: Vermont Academy of Arts and Sciences LV. 2020.

Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends in microbiology. 2016 Jun 1;24(6):490-502.

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020 Mar 16.

Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus research. 2008 Apr 1;133(1):74-87.

Wang M, Yan M, Xu H, Liang W, Kan B, Zheng B, Chen H, Zheng H, Xu Y, Zhang E, Wang H. SARS-CoV infection in a restaurant from palm civet. Emerging infectious diseases. 2005 Dec;11(12):1860.

Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Current tropical medicine reports. 2020 Mar 3:1-4.

Meselson M. Droplets and Aerosols in the Transmission of SARS-CoV-2. New England Journal of Medicine. 2020 Apr 15.

Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet infectious diseases. 2013 Sep 1;13(9):752-61.

Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama. 2020 Apr 21;323(15):1488-94.

De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology. 2016 Aug;14(8):523.

Ozili PK, Arun T. Spillover of COVID-19: impact on the Global Economy. Available at SSRN 3562570. 2020 Mar 27.

Draft landscape of COVID-19 candidate vaccines, 2 Jun 2020.

Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 Apr 9;19(5):305-6.

Afrough BS, Dowall, R. Hewson. Emerging viruses and current strategies for vaccine intervention. Clin Exp Immunol 2019; 196 (2): 157-166.

Paules CI, Marston HD, Eisinger RW, Baltimore D, Fauci AS. The pathway to a universal influenza vaccine. Immunity. 2017 Oct 17;47 (4): 599-603.

RTS, S Clinical Trials Partnership. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. New England Journal of Medicine. 2011 Nov 17; 365(20):1863-75.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020 Mar;579(7798):270-3.

Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019?nCoV in Italy: Where they come from?. Journal of medical virology. 2020 May;92(5):518-21.

Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infection, Genetics and Evolution. 2020 Apr 1;79: 104212.

Yuan M, Wu NC, Zhu X, Lee CC, So RT, Lv H, Mok CK, Wilson IA. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020 May 8;368(6491):630-3.

Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. EXCLI journal. 2020;19:410.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020 Mar;579(7798):270-3.

Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in microbiology. 2020 Feb 28;11:298.

Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert review of vaccines. 2012 Dec 1;11(12):1405-13.

Indian manufacturer shows high hopes of Covid-19 vaccine development; Published on June 03, 2020.

DeZure A, Graham BS. Vaccines for Emerging Viral Diseases. InThe Vaccine Book 2016 Jan 1 (pp. 543-560). Academic Press.

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 May 6.

HKU State Key Laboratory for Emerging Infectious Diseases joins global effort to develop covid-19 vaccine press release:

Shieber J. Codagenix raises $20 million for a new flu vaccine and other therapies. Tech Crunch (2020).

Smith TR, Patel A, Ramos S, Elwood D, Zhu X, Yan J, Gary EN, Walker SN, Schultheis K, Purwar M, Xu Z. Immunogenicity of a DNA vaccine candidate for COVID-19. Nature Communications. 2020 May 20;11(1):1-3.

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS-CoV-2 infection (COVID-19).

Pfizer and biontech dose first participants in the u.s. as part of global covid-19 mrna vaccine developmentprogram.,

Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nature Reviews Microbiology. 2009 Mar;7(3):226-36.

Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerging microbes & infections. 2020 Jan 1;9(1):275-7.

Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert review of vaccines. 2012 Dec 1;11(12):1405-13.

Du L, Tai W, Yang Y, Zhao G, Zhu Q, Sun S, Liu C, Tao X, Tseng CT, Perlman S, Jiang S. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nature communications. 2016 Nov 22;7(1):1-9.

Clover Biopharmaceuticals is developing a vaccine consisting of a trimerized SARS-CoV-2 S protein using their patented Trimer-Tag technology.

Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. The Lancet. 2004 Jun 26;363(9427):2122-7.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cellular & molecular immunology. 2020 Mar 19:1-8.

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine: trial-covid-19-vaccine

Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019 Jan;11(1):59.

Ad5-nCoV COVID-19 Vaccine:

Wang Y, Sun J, Zhu A, Zhao J, Zhao J. Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models. Journal of thoracic disease. 2018 Jul;10 (Suppl 19): S2260.